Overview: NGS Neurometabolic Disorders Sequencing TestIntroduction: The NGS Neurometabolic Disorders Sequencing Test sequences genes to diagnose neurometabolic disorders, causing seizures or developmental issues. Aligned with 2023 AAN guidelines, it uses PCR for high specificity, supporting neurological screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected neurometabolic disorders, such as neuronal ceroid lipofuscinosis.
Other Names: Neurometabolic NGS Assay, Neurometabolic Gene Panel.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Neurometabolic disorder sequencing began in the 2000s with metabolic research. NGS methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Sequences genes to diagnose neurometabolic disorders, guides treatment, and evaluates patients with seizures or developmental issues.
Test Parameters: 1. Neurometabolic Disorder Genes
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of seizures, developmental issues, or neurometabolic symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document seizures, developmental delays, vision loss, or family history of neurometabolic disorders. Include current medications, especially anticonvulsants.
Consent: Written consent required, detailing the tests purpose, neurometabolic disorder implications, and risks of sample collection.
Procedural Considerations: Uses next-generation sequencing to analyze neurometabolic genes (e.g., CLN3, PPT1). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for neurometabolic disorder diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Identified mutations confirm neurometabolic disorders, guiding supportive care or genetic counseling. Negative results may require metabolic testing.
Specialist Consultation: Consult a neurologist or geneticist for result interpretation and treatment planning.
Additional Supporting Tests: EEG, brain MRI, or urine organic acids to confirm neurometabolic disorder diagnosis.
Test Limitations: Not all neurometabolic disorders are genetic; clinical correlation is needed. Sample quality affects sensitivity.
References: AAN Neurometabolic Guidelines, 2023; Neurology, Mole SE, 2022.
